Skip to main content

Table 1 Characteristics of studies included in meta-analysis

From: Adverse events of video capsule endoscopy over the past two decades: a systematic review and proportion meta-analysis

  No. (%)
ECE GCE SBCE CCE After PCE Overall
Total
 Included studies 26 15 303 43 15 402
 Patient, n 2469 5197 91,069 5918 2624 107,277
 VCE, n 2473 5197 91,872 5963 2574 108,079
Study characteristics
 Midpoint of study period,
mean (range)
2008
(2005–2012)
2014
(2004–2017)
2008
(2001–2018)
2012
(2006–2017)
2011
(2006–2015)
2009
(2001–2018)
 Study design
  RCT 3 1 32 6 0 42
  Prospective 23 11 81 34 7 156
  Retrospective 0 3 190 3 8 204
 Region
  Europe 12 4 122 28 6 172
  North America 11 0 64 3 1 79
  Asia 2 11 105 11 7 136
  Oceania 1 0 7 0 0 8
  Latin America 0 0 3 0 0 3
  Africa 0 0 1 0 0 1
  Multiple 0 0 1 1 1 3
Patient characteristics
 Mean age, y 55.03 48.46 53.14 55.21 33.33 52.56
 Male sex, % 65.89 57.31 51.16 52.47 51.86 52.51
 Patient groups
  Population-based 23 13 155 37 6 234
  Known IBD 0 0 23 3 7 33
  OGIB 2 2 91 1 0 96
  Abdominal pain or diarrhea 0 0 8 0 0 8
  Suspected IBD 0 0 9 0 0 9
  NSAIDs users 0 0 8 0 0 8
  Mixed high-risk group 0 0 6 0 2 8
  Suspected tumor 1 0 3 2 0 6
  1. VCE, video capsule endoscopy; ECE, esophagus capsule endoscopy; GCE, gastral capsule endoscopy; SBCE, small bowel capsule endoscopy; CCE, colon capsule endoscopy; PCE, patency capsule endoscopy; IBD, inflammatory bowel disease; OGIB, obscure gastrointestinal bleeding; NSAIDs, non-steroidal anti-inflammatory drugs